PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results
- Successful Administration of IV Brincidofovir 50 mg in Ongoing Dose Escalation Study - - Demonstrates Favorable Safety and Tolerability Profile - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , March 02, 2017 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 37th Annual Health Care Conference
DURHAM, N.C. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and   commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
DURHAM, N.C. , Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on
View HTML
Toggle Summary Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings
-- Results show higher survival rate in adenovirus-infected patients with a virologic response to brincidofovir --  -- Mortality rates were lower in pediatric patients than in adult patients -- DURHAM, N.C. , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced the presentation
View HTML
Toggle Summary Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects
Study confirms drug levels for IV BCV 10 mg equivalent to oral BCV 100 mg   No gastrointestinal side effects seen with IV BCV at 10 and 25 mg doses DURHAM, N.C. , Jan. 06, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing
View HTML
Toggle Summary Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer
DURHAM, N.C. , Jan. 05, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced the appointments of Randall Lanier , PhD, as Chief Science Officer and Roy
View HTML
Toggle Summary Chimerix to Present at the 35th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C. , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company discovering and developing medicines that improve outcomes for immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix,
View HTML
Toggle Summary Chimerix Presents Data from a Preclinical Study of Intravenous Brincidofovir at AAPS
Data suggest that new intravenous formulation of brincidofovir may result in improved tolerability
View HTML
Toggle Summary Chimerix to Present at Upcoming Investor Conferences
DURHAM, N.C. , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present a corporate
View HTML
Toggle Summary Chimerix Announces Third Quarter 2016 Financial Results
- Brincidofovir IV Single and Multiple Dose Data Expected to Report Out in 2017 - - Comparative Adenovirus Trial with Oral Brincidofovir Expected to Start in 2017 - - CMX521 for Norovirus Advancing Toward the Clinic - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Nov.
View HTML